Clinical trials · Washington, D.C., DC
Neurofibromatosis Type 1 clinical trials in Washington, D.C.
We’re tracking 9 recruiting neurofibromatosis type 1 studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06507748Recruiting
Measuring pain with a finger device in NF1
This study tests a new way to measure pain and other sensations in people with NF1 using a device that clips onto a finger or toe. The device looks at how your pupil reacts to mild pulses, which may help doctors better understand your pain.
Washington D.C., District of ColumbiaAges 1–120 - NCT06541847RecruitingPhase 2
Testing HLX-1502 for NF1 with Plexiform Neurofibromas
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06188741RecruitingPhase 2
Selumetinib to prevent tumor growth in NF1 children
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
Washington D.C., District of ColumbiaAges 1–8 - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Washington D.C., District of ColumbiaAges 1 month–21 years - NCT06880991Recruiting
Study on visible tumors in neurofibromatosis type 1
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
Bethesda, MarylandAges 5–120 - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT04750928RecruitingPhase 1/Phase 2
Abemaciclib for NF1 tumors using pills and body scans
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
Bethesda, MarylandAges 12 years+ - NCT06222203Recruiting
Monitoring for tumor changes in people with NF1
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Bethesda, MarylandAges 3–120 - NCT04374305RecruitingPhase 2
Study tests targeted treatments for NF2 tumors
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
Baltimore, MarylandAges 12 years+
Hear when a new Neurofibromatosis Type 1 trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Neurofibromatosis Type 1 trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting neurofibromatosis type 1 studies listed above.
- National Institutes of Health Clinical Center · 6 studies
- Children's National Medical Center · 4 studies
- Johns Hopkins Hospital · 2 studies
- Johns Hopkins University · 2 studies
What taking part in a neurofibromatosis type 1 study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there neurofibromatosis type 1 clinical trials near Washington, D.C.?
- Yes. We're currently tracking 9 recruiting neurofibromatosis type 1 studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neurofibromatosis type 1 study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neurofibromatosis type 1 trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neurofibromatosis type 1 studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.